Fig. 4
Immune cell sub-populations associated to clinical benefit in peripheral blood mononuclear cells. a Frequency of T-cell subtypes determined by immunophenotyping of PBMC from peripheral blood in non-progressors (red) and progressors (blue) patients in the baseline sample. b Differential Treg percentage in baseline samples among progressors and non-progressors. c Non-progressors displayed a significant increase in central memory—and a trend to increase in effector memory—CD8+ T-cells 4 weeks after the first treatment dose, compared with progressors. d These changes were not evident for CD4+ T cells